NZ719724A - Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor - Google Patents

Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Info

Publication number
NZ719724A
NZ719724A NZ719724A NZ71972414A NZ719724A NZ 719724 A NZ719724 A NZ 719724A NZ 719724 A NZ719724 A NZ 719724A NZ 71972414 A NZ71972414 A NZ 71972414A NZ 719724 A NZ719724 A NZ 719724A
Authority
NZ
New Zealand
Prior art keywords
inh
use according
patients
organ
amr
Prior art date
Application number
NZ719724A
Other languages
English (en)
Inventor
Colin Broom
Marc Uknis
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ719724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority to NZ759187A priority Critical patent/NZ759187A/en
Publication of NZ719724A publication Critical patent/NZ719724A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ719724A 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor NZ719724A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ759187A NZ759187A (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US201462029086P 2014-07-25 2014-07-25
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Publications (1)

Publication Number Publication Date
NZ719724A true NZ719724A (en) 2022-08-26

Family

ID=52016153

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ759187A NZ759187A (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
NZ719724A NZ719724A (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ759187A NZ759187A (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Country Status (24)

Country Link
US (3) US9895428B2 (enExample)
EP (3) EP3071219B1 (enExample)
JP (5) JP6431912B2 (enExample)
KR (2) KR102312817B1 (enExample)
CN (2) CN105744949A (enExample)
AU (2) AU2014352846B2 (enExample)
BR (1) BR112016011499A2 (enExample)
CA (1) CA2930964A1 (enExample)
CY (1) CY1121298T1 (enExample)
DK (1) DK3071219T3 (enExample)
ES (1) ES2708655T3 (enExample)
HR (1) HRP20190184T1 (enExample)
HU (1) HUE041809T2 (enExample)
LT (1) LT3071219T (enExample)
ME (1) ME03318B (enExample)
MX (2) MX378834B (enExample)
NZ (2) NZ759187A (enExample)
PL (1) PL3071219T3 (enExample)
PT (1) PT3071219T (enExample)
RS (1) RS58343B1 (enExample)
SG (1) SG10201804326SA (enExample)
SI (1) SI3071219T1 (enExample)
SM (1) SMT201900042T1 (enExample)
WO (1) WO2015077543A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190184T1 (hr) * 2013-11-22 2019-03-22 Shire Viropharma Incorporated Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3121934A1 (en) * 2018-12-20 2020-06-25 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
CA3148600A1 (en) * 2019-08-08 2021-02-11 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2023551193A (ja) * 2020-11-20 2023-12-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 抗体関連型拒絶反応を処置するための方法
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
ES2516690T5 (es) 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
MX2008011054A (es) * 2006-03-02 2009-03-03 Alexion Pharma Inc Prolongacion de supervivencia de un aloinjerto, mediante la inhibicion de actividad de complemento.
JP6190368B2 (ja) * 2011-09-24 2017-08-30 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法
DK2964255T3 (da) * 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
LT3290046T (lt) 2013-03-15 2019-03-12 Shire Viropharma Incorporated C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai
HRP20190184T1 (hr) 2013-11-22 2019-03-22 Shire Viropharma Incorporated Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1

Also Published As

Publication number Publication date
CN105744949A (zh) 2016-07-06
CN111388655A (zh) 2020-07-10
SI3071219T1 (sl) 2019-03-29
US9895428B2 (en) 2018-02-20
HRP20190184T1 (hr) 2019-03-22
EP3494988B1 (en) 2022-08-03
KR102312817B1 (ko) 2021-10-13
EP3071219A1 (en) 2016-09-28
PT3071219T (pt) 2019-02-06
KR20160079821A (ko) 2016-07-06
EP3071219B1 (en) 2018-11-14
JP6620206B2 (ja) 2019-12-11
CY1121298T1 (el) 2020-05-29
EP3494988A1 (en) 2019-06-12
ME03318B (me) 2019-10-20
JP2022179637A (ja) 2022-12-02
JP6431912B2 (ja) 2018-11-28
KR102384814B1 (ko) 2022-04-08
JP2016537380A (ja) 2016-12-01
AU2014352846A1 (en) 2016-06-02
NZ759187A (en) 2022-08-26
KR20210125118A (ko) 2021-10-15
EP4162947A1 (en) 2023-04-12
BR112016011499A2 (pt) 2020-10-27
JP2021063141A (ja) 2021-04-22
MX378834B (es) 2025-03-11
AU2020200015A1 (en) 2020-01-30
RS58343B1 (sr) 2019-03-29
JP2019023233A (ja) 2019-02-14
HUE041809T2 (hu) 2019-05-28
PL3071219T3 (pl) 2019-04-30
SG10201804326SA (en) 2018-06-28
MX2016006656A (es) 2016-09-06
US20200360495A1 (en) 2020-11-19
AU2014352846B2 (en) 2019-10-03
AU2020200015B2 (en) 2022-03-10
CA2930964A1 (en) 2015-05-28
LT3071219T (lt) 2019-01-10
DK3071219T3 (en) 2019-02-25
WO2015077543A1 (en) 2015-05-28
US20180104319A1 (en) 2018-04-19
MX2021000332A (es) 2021-04-13
SMT201900042T1 (it) 2019-02-28
ES2708655T3 (es) 2019-04-10
JP2019001831A (ja) 2019-01-10
US20150147319A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
AU2020200015B2 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP5873047B2 (ja) 溶血性疾患の処置方法
KR101956585B1 (ko) 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
WO2015054569A1 (en) Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
HK40091830A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK40008415A (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK40008415B (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
KR20230110563A (ko) 항체 매개 거부 반응의 치료 방법
HK1229241A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241B (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210531

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2025 BY ANAQUA SERVICES

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2026 BY ANAQUA SERVICES

Effective date: 20251023